Allogene Therapeutics Inc header image

Allogene Therapeutics Inc

ALLO

Equity

ISIN null / Valor 43756548

NASDAQ (2026-11-06)
USD 1.04-4.59%

Allogene Therapeutics Inc
UMushroom community rating:

star star star star star
3.00 3 votes No rating yet
NegativeNeutralPositive

About company

Allogene Therapeutics Inc is a clinical-stage biotechnology firm focused on the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer treatment. The company operates at the forefront of cell therapy research, leveraging a comprehensive, in-house team for the discovery, translational research, development, and manufacturing of cell therapies. Allogene has established significant partnerships to enhance its technological capabilities and product pipeline. This includes a collaboration with Antion for miRNA technology to improve immune evasion strategies for AlloCAR T™ candidates, granting Allogene exclusive commercialization rights for certain targets. Additionally, the company has an exclusive agreement with Notch Therapeutics to develop induced pluripotent stem cell (iPSC) AlloCAR™ products for various cancers, utilizing Notch’s Engineered Thymic Niche (ETN) platform. Allogene is also co-developing ALLO-501 and ALLO-501A, anti-CD19 therapies, in partnership with Servier, based on a license from Cellectis, with exclusive rights in the U.S. and an option for global rights. These strategic collaborations underscore Allogene's commitment to advancing its portfolio of cancer therapies through innovative research and development initiatives.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-0.95%1Y
-67.1%3Y
-94.8%5Y

Performance

82.6%1Y
87.6%3Y
82.1%5Y

Volatility

Market cap

359 M

Market cap (USD)

Daily traded volume (Shares)

12,625,094

Daily traded volume (Shares)

1 day high/low

2.17 / 1.995

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.00

3 votes
Performance:
starstarstarstarstar
1.33
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
3.33
Nature:
starstarstarstarstar
3.00
C X
Switzerland, 20 Apr 2025
star star star star star
Good prospect for this or next year
C X
Switzerland, 28 Mar 2025
star star star star star
Expecting a good return, mid to long term.
C X
Switzerland, 24 Mar 2025
star star star star star
Recommended for long term investment.

EQUITIES OF THE SAME SECTOR

Biogen Inc
Biogen Inc Biogen Inc Valor: 1720684
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.81%USD 248.35
Zydus Lifesciences Limited
Zydus Lifesciences Limited Zydus Lifesciences Limited Valor: 29835501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%INR 1,195.00
IPCA Laboratories Limited
IPCA Laboratories Limited IPCA Laboratories Limited Valor: 115718957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%INR 1,942.95
AnaptysBio, Inc.
AnaptysBio, Inc. AnaptysBio, Inc. Valor: 29675116
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.91%USD 46.45
LeMaitre Vascular inc
LeMaitre Vascular inc LeMaitre Vascular inc Valor: 2755054
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.11%USD 80.89
GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.16%USD 50.33
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited Valor: 3195888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%INR 2,592.85
GSK PLC
GSK PLC GSK PLC Valor: 119642297
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 18.90
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.77%GBP 16.50
Piramal Pharma Limited
Piramal Pharma Limited Piramal Pharma Limited Valor: 114197705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.17%INR 239.20